Pregabalin (Epilepsy) updated on 04-22-2025

Neuro-developmental disorders (as a whole)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18748
R79717		 Moore (Pregabalin) (Epilepsy) (Controls exposed to LTG), 2025 Early childhood developmental concerns (any developmental concerns on any domain at the 27–30 month assessment offered to all children) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 3.45 [1.73;6.88] C
excluded (control group) 		20/37   90/354 110 37
ref
S18747
R79714		 Moore (Pregabalin) (Epilepsy) (Controls unexposed, sick), 2025 Early childhood developmental concerns (any developmental concerns on any domain at the 27–30 month assessment offered to all children) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes Matched 3.08 [1.50;6.33] 20/37   102/370 122 37
ref
Total 1 studies 3.08 [1.50;6.33] 122 37
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Moore (Pregabalin) (Epilepsy) (Controls unexposed, sick), 2025Moore, 2025 1 3.08[1.50; 6.33]122370%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: low0.910.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Pregabalin) (Epilepsy) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 3.08[1.50; 6.33]12237 -NAMoore (Pregabalin) (Epilepsy) (Controls unexposed, sick), 2025 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 3.08[1.50; 6.33]12237 -NAMoore (Pregabalin) (Epilepsy) (Controls unexposed, sick), 2025 1 Tags Adjustment   - Yes  - Yes 3.08[1.50; 6.33]12237 -NAMoore (Pregabalin) (Epilepsy) (Controls unexposed, sick), 2025 1 MatchedMatched 3.08[1.50; 6.33]12237 -NAMoore (Pregabalin) (Epilepsy) (Controls unexposed, sick), 2025 1 All studiesAll studies 3.08[1.50; 6.33]12237 -NAMoore (Pregabalin) (Epilepsy) (Controls unexposed, sick), 2025 10.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 18748

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 3.08[1.50; 6.33]12237 -NAMoore (Pregabalin) (Epilepsy) (Controls unexposed, sick), 2025 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 3.45[1.73; 6.88]11037 -NAMoore (Pregabalin) (Epilepsy) (Controls exposed to LTG), 2025 10.510.01.0